Adaptive Biotechnologies presents studies demonstrating utility of Immunosequencing

May 15, 2016 – SEATTLE. Adaptive Biotechnologies, the leader in combining next generation sequencing (NGS) and expert bioinformatics to profile T- and B-cell receptors of the adaptive immune system, will present data demonstrating how profiling the T-cell repertoire has the potential to advance diagnostic development and therapeutic discovery in immune-mediated diseases at the American Association of Immunologists (AAI) Annual Meeting in Seattle, May 13-17, 2016.

“As evidenced by these data, assessing the presence of associated T-cell responses can serve as a powerful diagnostic classifier in infectious diseases,” says Dr. Harlan Robins, Chief Scientific Officer and Co-Founder of Adaptive Biotechnologies. “We are also continuing to expand our proprietary immunosequencing technology into a highly useful tool for therapeutic discovery, changing the paradigm of treatment for infectious diseases, autoimmunity and cancer.”

Adaptive is also hosting an exhibitor workshop at AAI on Sunday, May 15, 1:45-2:30 p.m. Exhibitor Workshop Room 2, featuring Catherine Sanders, PhD from Adaptive Biotechnologies, to discuss how utilizing immunosequencing can accelerate innovation and discovery.

Representatives from Adaptive Biotechnologies will be exhibiting at AAI booth #446 to answer questions about its immunosequencing technology.

Oral Presentations:

Abstract #209.04: A scalable multiplex assay enabling assessment of T cell receptor specificity to hundreds of self- and pathogen-derived antigensTuesday, May 17, 2016, 11:00-11:15 a.m.Room 611-612Presenter: Mark Klinger, Adaptive Biotechnologies

Poster Presentations:

Abstract #148.11 - Immunosequencing reveals diagnostic signatures of pathogen infection and HLA type in the T-cell Receptor RepertoireSunday, May 15, 2016, 2:30-3:45 p.m.Poster# 2777, Poster HallPresenter: Will DeWitt, Adaptive Biotechnologies

Abstract #209.04: A scalable multiplex assay enabling assessment of T cell receptor specificity to hundreds of self- and pathogen-derived antigensMonday, May 16, 2016, 2:30-3:45 p.m.Poster# 2232, Poster HallPresenter: Mark Klinger, Adaptive Biotechnologies

 

Source: Adaptive Biotechnologies